Market Place
Sourcing Support
CuraSen Doses First Subject With CuraAX (CST-3056) In Ph 1 Trial
20 Feb 2025 //
BUSINESSWIRE
CuraSen Therapeutics Appoints Kathleen Sereda Glaub CEO
15 Oct 2024 //
BUSINESSWIRE
CuraSen Announces Presentation of Positive Phase 2a Data with CST-2032/CST-107
07 Mar 2024 //
BUSINESSWIRE
CuraSen Announces Investment from Alzheimer’s Drug Discovery Foundation
09 Oct 2023 //
BUSINESSWIRE
CuraSen to Present Phase 2 Data Showing Mood Benefit with CST-103/CST-107
30 Mar 2023 //
BUSINESSWIRE
CuraSen reports positive data from Parkinson’s disease oral therapy trial
20 Dec 2022 //
CLINICALTRIALSARENA
CuraSen Announces Successful Completion of PII with CST-103/CST-107 Treatment
19 Dec 2022 //
BUSINESSWIRE
CuraSen Announces First Patients Treated with Novel Combination Therapy
07 Sep 2022 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.